BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Doxorubicin
,
rs4950928
,
ZBTB7A
,
glucose metabolic process
,
Hepatitis
,
Lymphocyte
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
JAKs
Summary
General Info
Curated Studies
Most Correlated Studies
Ovarian cancer model treated with JAK inhibitor AZD1480
White-to-brown metabolic conversion of adipocytes by JAK inhibition
Epiblast stem cell expression profiles following induced JAK/STAT3 signaling
Skin biopsies of atopic dermatitis patients treated with oral dual JAK/SYK inhibitor ASN002
Dermal papilla cells from donors in spheres treated with tofacitinib or ruxolitinib
Explore Curated Studies Results
Literature
Most Relevant Literature
Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Imm…
JAK inhibitors for the treatment of vitiligo.
JAK inhibitors: Is specificity at all relevant?
JAK inhibitors ∼ overview∼.
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
JAK Inhibition in Ulcerative Colitis
JAK Inhibitor Treatment in AGS
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
Cutaneous JAK in Vitiligo and Acne Vulgaris.
Effect of the Inhibitors of the Way JAK-STAT on Regulatory B Cells
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ